

Supplementary Table. Cox proportional hazards regression and logistic regression analysis for the association of risk count with biopsy reclassification stratified by the number of prostate-specific antigen velocities calculated, Johns Hopkins Active Surveillance Program 1995-2012.

Risk Count ^c	Cox Proportional Hazards Regression						Logistic Regression						
	Unadjusted			Adjusted ^a			Unadjusted			Adjusted ^b			
	HR	(95% CI)	p-value	HR	(95% CI)	p-value	OR	(95% CI)	p-value	OR	(95% CI)	p-value	
3 PSAVs Calculated^d		N=275											
Any Criteria	1	1.79	(0.93-3.46)	0.081	1.53	(0.77-3.04)	0.229	1.69	(0.81-3.50)	0.16	1.68	(0.76-3.72)	0.204
	2	4.30	(2.26-8.18)	<0.01	3.73	(1.75-7.97)	<0.01	4.72	(2.21-10.08)	<0.01	5.76	(2.16-15.41)	<0.01
	3	5.02	(1.99-12.67)	<0.01	4.63	(1.54-13.87)	<0.01	7.00	(1.92-25.50)	<0.01	8.70	(1.92-39.34)	<0.01
GSR^e	1	1.71	(0.70-4.22)	0.241	1.75	(0.70-4.38)	0.235	1.52	(0.59-3.92)	0.385	1.64	(0.61-4.44)	0.331
	2	3.16	(1.28-7.82)	0.013	3.96	(1.35-11.62)	0.012	3.01	(1.16-7.82)	0.024	4.23	(1.33-13.46)	0.015
	3	6.41	(1.84-22.31)	<0.01	7.45	(1.60-34.71)	0.011	5.07	(1.21-21.18)	0.026	7.52	(1.42-39.83)	0.018
2 PSAVs Calculated		N=102											
Any Criteria	1	2.25	(0.96-5.23)	0.061	1.91	(0.67-5.41)	0.225	2.59	(0.94-7.09)	0.065	1.94	(0.54-7.00)	0.313
	2	2.35	(0.95-5.87)	0.066	1.61	(0.46-5.58)	0.455	7.00	(1.94-25.25)	<0.01	4.65	(0.79-27.30)	0.089
GSR	1	3.35	(0.71-15.72)	0.126	2.10	(0.28-16.02)	0.473	2.60	(0.52-12.96)	0.244	1.42	(0.20-9.90)	0.726
	2	6.72	(1.44-31.31)	0.015	2.84	(0.31-25.90)	0.356	10.64	(1.97-57.44)	<0.01	3.91	(0.40-38.50)	0.243
1 PSAV Calculated		N=206											
Any Criteria	1	0.99	(0.68-1.45)	0.972	1.71	(1.06-2.75)	0.027	0.94	(0.55-1.64)	0.838	1.75	(0.77-3.98)	0.184
GSR	1	2.07	(1.16-3.68)	0.013	2.63	(1.32-5.25)	<0.01	1.87	(0.99-3.53)	0.054	2.39	(1.01-5.64)	0.047

^aCox proportional hazards regression adjusted for age at diagnosis, race, prostate-specific antigen density at diagnosis, overall prostate-specific antigen velocity during follow-up, and presence of cancer on first surveillance biopsy

^bLogistic regression adjusted for age at diagnosis, race, prostate-specific antigen density at diagnosis, overall prostate-specific antigen velocity during follow-up, presence of cancer on first surveillance biopsy, and length of time periods

^cCompared to patients with a total Risk Count of 0

^dPSAV = prostate-specific antigen velocity

^eGSR = Gleason score reclassification